4//SEC Filing
HUMAN GENOME SCIENCES INC 4
Accession 0001225208-12-016950
CIK 0000901219operating
Filed
Jul 31, 8:00 PM ET
Accepted
Aug 1, 11:53 AM ET
Size
21.6 KB
Accession
0001225208-12-016950
Insider Transaction Report
Form 4
Bateson Susan D.
Senior Vice President
Transactions
- Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−64,304$916,332→ 0 totalExercise: $4.92Exp: 2018-03-10→ Common Stock (64,304 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−14,779$210,601→ 0 totalExercise: $10.62Exp: 2017-03-10→ Common Stock (14,779 underlying) - Disposition from Tender
Common Stock
2012-07-30$14.25/sh−62,270$887,348→ 0 total - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−67,997$968,957→ 0 totalExercise: $0.52Exp: 2019-03-10→ Common Stock (67,997 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−2,120$30,210→ 0 totalExercise: $10.89Exp: 2016-03-14→ Common Stock (2,120 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−108,000$1,539,000→ 0 totalExercise: $8.23Exp: 2022-03-10→ Common Stock (108,000 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−49,354$703,295→ 0 totalExercise: $12.56Exp: 2015-01-17→ Common Stock (49,354 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−76,923$1,096,153→ 0 totalExercise: $12.38Exp: 2013-12-10→ Common Stock (76,923 underlying)
Footnotes (7)
- [F1]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $83408.26 representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F2]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $53,647.77, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F3]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $599,956.32, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F4]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $933,598.81 representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F5]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $650,160.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F6]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $7,123.20 representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F7]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $143,846.01, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
Documents
Issuer
HUMAN GENOME SCIENCES INC
CIK 0000901219
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000901219
Filing Metadata
- Form type
- 4
- Filed
- Jul 31, 8:00 PM ET
- Accepted
- Aug 1, 11:53 AM ET
- Size
- 21.6 KB